Difference between revisions of "Yu D, et al. Lab. Invest. (2014) cited as Ref 351 in DOI: 10.1038/s41392-020-0110-5 (Q9614)"
Jump to navigation
Jump to search
(Created claim: Publication Date (P100): 2014, #quickstatements; #temporary_batch_1590002823654) |
(Created claim: Fourth Author string (P152): Lee YC, #quickstatements; #temporary_batch_1590155310798) |
||
| (4 intermediate revisions by the same user not shown) | |||
| Property / Published In Name String | |||
| + | Lab. Invest. | ||
| Property / Published In Name String: Lab. Invest. / rank | |||
| + | Normal rank | ||
| Property / Volume | |||
| + | 94 | ||
| Property / Volume: 94 / rank | |||
| + | Normal rank | ||
| Property / title | |||
| + | miR-106b modulates cancer stem cell characteristics through TGF-beta/Smad signaling in CD44-positive gastric cancer cells (English) | ||
| Property / title: miR-106b modulates cancer stem cell characteristics through TGF-beta/Smad signaling in CD44-positive gastric cancer cells (English) / rank | |||
| + | Normal rank | ||
| Property / Page(s) | |||
| + | 1370-1381 | ||
| Property / Page(s): 1370-1381 / rank | |||
| + | Normal rank | ||
| Property / Fourth Author string | |||
| + | Lee YC | ||
| Property / Fourth Author string: Lee YC / rank | |||
| + | Normal rank | ||
Latest revision as of 13:49, 22 May 2020
Cited in: "Targeting cancer stem cell pathways for cancer therapy" in Signal Transduct Target Ther; 2020 ; 5 8
| Language | Label | Description | Also known as |
|---|---|---|---|
| English |
Yu D, et al. Lab. Invest. (2014) cited as Ref 351 in DOI: 10.1038/s41392-020-0110-5
|
Cited in: "Targeting cancer stem cell pathways for cancer therapy" in Signal Transduct Target Ther; 2020 ; 5 8
|
Statements
Yu D
0 references
Shin HS
0 references
Lee YS
0 references
2014
0 references
Lab. Invest.
0 references
94
0 references
miR-106b modulates cancer stem cell characteristics through TGF-beta/Smad signaling in CD44-positive gastric cancer cells (English)
0 references
1370-1381
0 references
Lee YC
0 references
